6 research outputs found
Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria
Context: Support for non-Hodgkin\u2032s lymphoma (NHL) with large
cells that is refractory or relapsed after first-line chemotherapy
poses a greater therapeutic problem with bone marrow transplant therapy
or when old age is a contra-indication for high-dose chemotherapy,
especially among developing countries such as Algeria. Aim: To show
that the regimen, including gemcitabine, could be more effective in
treating elderly patients with diffuse large B-cell lymphoma (DLBCL) in
relapse / refractory, without complete remission, when compared with
the ESHAP (etoposide, cisplatine, solumedrol, aracytine) regimen.
Materials and Methods: Ninety-six patients in the age group of 60-70
years were volunteers for a prospective randomized single-blind study,
carried out for three years. Patients were divided into two groups by
the drawing of lots. The first group (GA, n = 48, relapse; n = 27
[56.3%], refractory; n = 21 [43.7%]) received treatment with ESHAP
protocol and the second one (GB, n = 48, relapse; n = 28 [58%],
refractory; n = 20 [42%]) with GPD (gemcitabine, dexamethasone,
cisplatine) protocol. Results: The overall response rates and mean
survival at three years were significantly higher among patients
subjected to GPD treatment compared with those subjected to ESHAP
treatment (63% vs. 55%, P = 0.01 and 20.5% [95% CI 16.5-24.5] vs. 11.8%
[8.9-14.6], respectively). Additionally, three-year progression-free
and event-free survival rates were 20.5% (16.3-24) and 19.7%
(15.9-23.5), respectively, for the GPD regimen and 10.9% (8.2-13.7) and
11.1% (95% CI 8.5-13.7), respectively, for the ESHAP regimen. Moreover,
the GPD regimen was associated with improving overall survival
(RR=2.02, 95% CI 1.59-2.56; P = 0.000), event-free survival (2.03,
1.64-2.52; P < 0.001) and progression-free survival (1.86,
1.46-2.37; P < 0.001). Conclusion: In cases of contra-indication for
high-dose chemotherapy for elderly patients with DLBCL, without
complete remission, the Gemcitabine-based therapy protocol represents a
more effective and less toxic than that of ESHAP
Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria
Context: Support for non-Hodgkin′s lymphoma (NHL) with large
cells that is refractory or relapsed after first-line chemotherapy
poses a greater therapeutic problem with bone marrow transplant therapy
or when old age is a contra-indication for high-dose chemotherapy,
especially among developing countries such as Algeria. Aim: To show
that the regimen, including gemcitabine, could be more effective in
treating elderly patients with diffuse large B-cell lymphoma (DLBCL) in
relapse / refractory, without complete remission, when compared with
the ESHAP (etoposide, cisplatine, solumedrol, aracytine) regimen.
Materials and Methods: Ninety-six patients in the age group of 60-70
years were volunteers for a prospective randomized single-blind study,
carried out for three years. Patients were divided into two groups by
the drawing of lots. The first group (GA, n = 48, relapse; n = 27
[56.3%], refractory; n = 21 [43.7%]) received treatment with ESHAP
protocol and the second one (GB, n = 48, relapse; n = 28 [58%],
refractory; n = 20 [42%]) with GPD (gemcitabine, dexamethasone,
cisplatine) protocol. Results: The overall response rates and mean
survival at three years were significantly higher among patients
subjected to GPD treatment compared with those subjected to ESHAP
treatment (63% vs. 55%, P = 0.01 and 20.5% [95% CI 16.5-24.5] vs. 11.8%
[8.9-14.6], respectively). Additionally, three-year progression-free
and event-free survival rates were 20.5% (16.3-24) and 19.7%
(15.9-23.5), respectively, for the GPD regimen and 10.9% (8.2-13.7) and
11.1% (95% CI 8.5-13.7), respectively, for the ESHAP regimen. Moreover,
the GPD regimen was associated with improving overall survival
(RR=2.02, 95% CI 1.59-2.56; P = 0.000), event-free survival (2.03,
1.64-2.52; P < 0.001) and progression-free survival (1.86,
1.46-2.37; P < 0.001). Conclusion: In cases of contra-indication for
high-dose chemotherapy for elderly patients with DLBCL, without
complete remission, the Gemcitabine-based therapy protocol represents a
more effective and less toxic than that of ESHAP
A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group
BACKGROUND AND OBJECTIVESIn Algeria, the incidence of hematologic malignancies has been difficult to estimate for many years. Today, many hematological centers, including 14 university hospitals, have been developed in the entire north and have useful epidemiological data pertinent to acute myeloid leukemia (AML). We studied the incidence of AML and its subtypes, age distribution, geographic distribution and trends in the rate of diagnosis over the last 5 years in Algeria. Secondary goals were to study trends of referral of AML cases from various regions to specific centers to assess the needs for health infrastructure and change of current practices.DESIGN AND SETTINGRetrospective analysis of nationwide survey of all adult cases of AML (>16years) diagnosed between 1 January 2006 and 31 December 2010.PATIENTS AND METHODSA survey form was distributed to all departments of hematology at the 15 participating centers.RESULTSThe 1426 cases of AML diagnosed during the study period represented an annual incidence of 0.91/100 000 persons with a male to female (M/F) ratio of 1:16 and a median age of 45 years (range, 16-82years). Nationally, 20% of cases AML were diagnosed in the whole western region of the country, 47% in the central and 33% in the east. There was a trend of continuous increase in the rate with age and in the rate of diagnosis over the last 5 years. The most common subtype was M2, followed by M4 and M5.CONCLUSIONAn overall increase in the number of AML patients diagnosed nationwide over the last five years indicates a need for additional health care resources including curative and therapy-intense strategies, such as stem cell transplant facilities to optimize outcome. The relatively younger age of patients compared to the Western countries may be due to the demographic composition of our population
PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria
Context: Support for non-Hodgkin′s lymphoma (NHL) with large
cells that is refractory or relapsed after first-line chemotherapy
poses a greater therapeutic problem with bone marrow transplant therapy
or when old age is a contra-indication for high-dose chemotherapy,
especially among developing countries such as Algeria. Aim: To show
that the regimen, including gemcitabine, could be more effective in
treating elderly patients with diffuse large B-cell lymphoma (DLBCL) in
relapse / refractory, without complete remission, when compared with
the ESHAP (etoposide, cisplatine, solumedrol, aracytine) regimen.
Materials and Methods: Ninety-six patients in the age group of 60-70
years were volunteers for a prospective randomized single-blind study,
carried out for three years. Patients were divided into two groups by
the drawing of lots. The first group (GA, n = 48, relapse; n = 27
[56.3%], refractory; n = 21 [43.7%]) received treatment with ESHAP
protocol and the second one (GB, n = 48, relapse; n = 28 [58%],
refractory; n = 20 [42%]) with GPD (gemcitabine, dexamethasone,
cisplatine) protocol. Results: The overall response rates and mean
survival at three years were significantly higher among patients
subjected to GPD treatment compared with those subjected to ESHAP
treatment (63% vs. 55%, P = 0.01 and 20.5% [95% CI 16.5-24.5] vs. 11.8%
[8.9-14.6], respectively). Additionally, three-year progression-free
and event-free survival rates were 20.5% (16.3-24) and 19.7%
(15.9-23.5), respectively, for the GPD regimen and 10.9% (8.2-13.7) and
11.1% (95% CI 8.5-13.7), respectively, for the ESHAP regimen. Moreover,
the GPD regimen was associated with improving overall survival
(RR=2.02, 95% CI 1.59-2.56; P = 0.000), event-free survival (2.03,
1.64-2.52; P < 0.001) and progression-free survival (1.86,
1.46-2.37; P < 0.001). Conclusion: In cases of contra-indication for
high-dose chemotherapy for elderly patients with DLBCL, without
complete remission, the Gemcitabine-based therapy protocol represents a
more effective and less toxic than that of ESHAP